Intensity Therapeutics (INTS) Q3 2026 earnings review
Intensity Therapeutics restarts both cancer trials, but cash keeps shrinking
Intensity Therapeutics, a clinical-stage developer of injectable cancer drugs, restarted patient recruiting in both of its trials while its cash balance kept shrinking. Third-quarter net loss widened to $3.5 million as clinic reactivations and a new drug batch pushed research spending up 56%. Chief executive Lewis H. Bender raised $1.5 million by selling new shares, leaving $8.5 million in cash at quarter-end.
| Cash and cash equivalents | $8.5M down from $9.5M last quarter |
|---|---|
| Research and development spending | $2.4M +56% from a year ago |
| Net loss | $3.5M $2.7M loss a year ago |
| INVINCIBLE-4 enrollment outlook | Unchanged targeting completion by end of 2027 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because restarting the trials on a shoestring budget has not solved the funding shortage. Opening a handful of U.S. sarcoma clinics and a first French breast cancer clinic fulfills last quarter's plan, and by our math cash use before stock sales was about $2.5 million, below the $3 million pace the prior outlook implied. One caution: unpaid vendor bills jumped by more than $600,000, and the share count nearly doubled from a year ago.
The question now is whether early breast cancer data can bring in a partner before steady share sales dilute investors further. Either the single-injection dose proves safe enough to attract a deal, or the company stays on a cycle of small stock offerings that cannot fund the full Phase 3 sarcoma study. The independent safety board's review in the first quarter of 2027 will provide the first test.
🐂 Bull Case
Both Cancer Trials Resumed Recruiting Patients
Intensity Therapeutics develops INT230-6, a cancer drug injected directly into tumors to kill cancer cells and trigger an immune response. The biotechnology group had paused both of its main clinical studies in 2025 to save cash and fix a skin side effect, so restarting them was the key goal for the quarter.
In July 2026, the drug developer restarted patient treatment in INVINCIBLE-4, its Phase 2 study in early-stage triple-negative breast cancer, and opened its first French clinic in August. For INVINCIBLE-3, its Phase 3 study in soft tissue sarcoma (a cancer of muscle and fat tissue), it resumed enrollment work at limited U.S. clinics.
"Several sites are now activated and patients have been identified," the company said of the sarcoma trial, while chief executive Lewis H. Bender noted that he "had follow-up discussions with several organizations at ESMO from our prior meetings at ASCO and BIO" regarding potential partnerships.
What to watch: the exact count of newly dosed patients in both studies in the full quarterly filing or year-end report. Identifying candidates is an early step, so confirmed dosing numbers will show whether clinics are actually putting patients on the drug.
Share Sales Offset Part of the Cash Drain
Intensity sells new shares directly into the stock market through an at-the-market (ATM) facility worth up to $60 million to pay for its trials. Because the company has no commercial products or revenue, these incremental stock sales are its only current source of funding while it looks for a partner.
During the third quarter, the drug developer raised $1.5 million in net proceeds under this facility, bringing its nine-month total to $3.2 million. By our math, taking the $1.0 million drop in cash alongside the $1.5 million raised points to about $2.5 million in quarterly cash use, below the $3.0 million pace the prior outlook implied.
That lower cash drain does not mean the trial restart is cheap, because unpaid vendor bills rose by more than $600,000 during the quarter. Delaying bill payments held down cash use for three months, and the $1.5 million raised covers less than two months of operating expenses.
What to watch: net cash used in operating activities in the third-quarter Form 10-Q filing. That statement will separate actual cash spent on operations from timing shifts in unpaid clinical bills.
🐻 Bear Case
Cash Shrinks as Trial Restart Lifts Spending
Restarting clinical trials requires upfront spending on drug supply and hospital sites before a company knows if it can pay for the full study. Intensity previously told investors it needs about $30 million in extra funding to finish its 333-patient Phase 3 sarcoma trial, far above the cash it holds today.
- Cash and cash equivalents: $8.5 million, down 11% from $9.5 million last quarter
- Research and development spending: $2.4 million, up 56% from a year ago and up 33% from last quarter
- Total operating expenses: $3.6 million, up 33% from a year ago
Research spending rose because the company reactivated U.S. sarcoma clinics, started a new INT230-6 manufacturing batch, and accrued employee bonuses. Even with higher spending, the trial remains on a tight leash: "Increased site activation and patient enrollment rates are expected as sufficient incremental funding is obtained," the release noted.
What to watch: year-end cash and any partnership upfront payment by the fourth-quarter report. Without a large cash infusion, the company can run only a fraction of its planned sarcoma clinics while cash continues to fall.
Steady Share Sales Nearly Doubled the Share Count
Selling shares through an at-the-market facility keeps cash coming in, but it also spreads any future drug value across many more shares. Meanwhile, Intensity must maintain enough stockholders' equity — its assets minus its liabilities — to meet Nasdaq Capital Market listing rules.
Weighted average shares rose 89% from a year ago and 20% from last quarter to 3.26 million. That rapid increase in share count made the net loss per share shrink by 30% to $1.09, even though the company's actual dollar net loss grew by 33% to $3.5 million.
Because the $3.5 million quarterly loss outpaced the $1.5 million raised from stock sales, stockholders' equity fell 17% from last quarter to $7.7 million. By our math, about $56.7 million remains unused on the $60 million equity facility, so relying on it to fund trials will continue to dilute current shareholders.
What to watch: total shares outstanding and stockholders' equity in the fourth-quarter report. Continued quarterly losses without a partnership will push equity lower and test exchange listing standards again.
Breast Cancer Dosing Fix Still Lacks Proof
In the INVINCIBLE-4 breast cancer study, Intensity highlights preliminary results from the first 14 patients showing a 71% pathological complete response (the absence of live cancer at surgery) with INT230-6, versus 42% for standard therapy alone. Bender said these results give clinics good reason to enroll patients.
However, those 14 patients received an older two-injection regimen that caused skin irritation and forced a ten-month trial pause. Clinics are now giving a single injection with less drug per tumor volume, and the Swiss Cancer Institute formed an independent board "to review the safety data and images of these newly treated patients to assess whether the skin irritation issue has been resolved."
That means the company does not yet know if the lighter single dose avoids skin damage or still clears tumors at the 71% rate. Intensity has not reported efficacy numbers for any patient treated under the new dose.
What to watch: the independent safety board's review in the first quarter of 2027. An unfavorable safety finding would disrupt the breast cancer trial a second time and delay the end-2027 enrollment goal.
Risks this quarter didn't answer
Four standing items from prior quarters received no new figures in the third-quarter press release because full financial notes and call remarks were not included.
- Operating cash burn: the release omitted the cash flow statement; the Form 10-Q will show exact nine-month operating cash use.
- Newly dosed patient counts: the release gave no headcount for patients treated under the amended protocols in either trial; the Form 10-Q or year-end update will test progress.
- Pre-pause sarcoma patients: the release repeated that 21 patients enrolled before the pause without reconciling earlier 23-patient disclosures or confirming if they stay in the final statistical analysis.
- Going-concern status and patent exposure: the release did not update the standing going-concern warning or intellectual property risks in Russia and Israel, which live in the Form 10-Q footnotes.
💲 Other KPIs
Unpaid bills to vendors jumped 63.6% from last quarter and 183.2% from $583,000 at the end of 2025. Accounts payable represents short-term bills the drug developer owes to clinical contractors and suppliers. Stretching out these payments conserved cash during the third quarter as research and manufacturing work ramped up, but those bills must be paid in coming quarters.
Overhead spending held nearly unchanged, rising 1.2% from $1.18 million a year ago and dipping 4.6% from $1.25 million in the second quarter. General and administrative expenses cover executive pay, legal fees, insurance and public company costs. Keeping overhead near $1.2 million a quarter allowed almost all of the quarter's spending increase to go toward clinical trials.
🔮 Guidance
Unchanged. Intensity is still "currently targeting complete enrollment by the end of 2027" for its 54-patient Phase 2 breast cancer trial. The company previously moved this target twice — from early 2026 to late 2026, and then to the end of 2027 after the nine-month dosing pause. Hitting the current date requires steady recruiting across its Swiss and newly opened French clinics.
New. "We plan to provide an update upon completion of IDMB review in the first quarter of 2027," the biotechnology group said. The independent board is reviewing safety data and tumor images from patients treated under the lower-volume, single-injection breast cancer protocol. Chief executive Lewis H. Bender said a positive report will give the team confidence that the skin irritation problem is solved.
Unchanged. The company repeated that faster clinic openings and patient recruiting in its Phase 3 sarcoma study depend on raising additional capital. While U.S. clinics have begun identifying patients and filings to restart in Europe and Canada are underway, full execution of the trial remains gated by the roughly $30 million funding gap.
❓ Key Questions
How many new patients were dosed this quarter?
The release says U.S. sarcoma sites identified patients and European breast cancer sites resumed treatment, but it gives no patient counts. Exact numbers for both trials are needed to judge whether the end-2027 breast cancer target is realistic.
What was operating cash burn excluding unpaid bills?
Accounts payable jumped by $642,000 in the third quarter, which held down the drop in cash. Investors need the Form 10-Q cash flow statement to see if monthly operating cash burn is running at the $1 million pace indicated last quarter.
Have cancer conference talks produced a partnership term sheet?
Chief executive Lewis H. Bender noted follow-up meetings with several organizations at the European oncology conference. With $8.5 million in cash and a $30 million Phase 3 funding need, only a concrete upfront deal changes the financing picture.
How will the 21 pre-pause sarcoma patients be analyzed?
Intensity modified the INVINCIBLE-3 trial rules during the 16-month pause. Management still has not clarified whether the 21 patients enrolled before March 2025 will count in the main survival analysis or require extra enrollment to replace them.